antiphospholipid syndrome aps epidemiology forecast

Antiphospholipid Syndrome Epidemiology

• According to DelveInsight’s analysis, the total prevalent cases of APS were ~ 310,800 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.

• APS is more prevalent in Asian countries such as Japan due to higher detection rates, increased awareness of autoimmune disorders, genetic predisposition, and a growing burden of associated conditions such as Systemic Lupus Erythematosus.

• According to a study by Dabitt et al. (2021), the prevalence of antiphospholipid antibodies in patients with obstetric morbidity was 6–9%, while in arterial events and venous thromboembolism is 9–10%.

• Antiphospholipid syndrome affects 3 to 5 times as many women as men. Although there's no cure for APS, the risk of developing blood clots can be greatly reduced if it's correctly diagnosed.

• Females face a higher lifetime risk of developing APS and experience a greater disease burden compared to males. This disparity is largely attributed to the higher prevalence of autoimmune conditions in women, hormonal influences, and reproductive factors, as women are more likely to experience pregnancy-related complications such as recurrent miscarriages and obstetric morbidity associated with APS.

• Rising awareness, improved diagnostic capabilities, increasing prevalence of autoimmune disorders such as Systemic Lupus Erythematosus, and persistent thrombotic risk factors are expected to sustain the global APS burden over the next decade. Strengthening early diagnosis, optimizing long-term anticoagulation strategies, and advancing targeted therapies will remain key determinants of future trends.

Antiphospholipid Syndrome Epidemiology Forecast in 7MM

• 2025 Prevalent Cases of APS: ~ 310,800

• APS Growth Rate (2026–2036): ~0.7%CAGR

DelveInsight's ‘Antiphospholipid Syndrome (APS) Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the APS, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Antiphospholipid Syndrome Understanding 

APS Overview

APS is an autoimmune disorder in which abnormal antibodies increase the risk of blood clots in arteries and veins. It can lead to complications such as deep vein thrombosis, stroke, and recurrent pregnancy loss. APS is caused by immune system dysfunction and may occur alone or with other autoimmune diseases. Diagnosis is based on blood tests for specific antibodies, and treatment mainly involves long-term anticoagulation to prevent clot formation.

APS Diagnosis

APS is diagnosed based on clinical history and blood tests, often suspected in patients with unexplained blood clots or recurrent pregnancy loss. Diagnosis is confirmed by detecting antiphospholipid antibodies such as lupus anticoagulant, anti-cardiolipin, and anti-β2 glycoprotein I on two occasions at least 12 weeks apart. Imaging tests may be used to identify associated thrombosis.

Further details are provided in the report.

Antiphospholipid Syndrome Epidemiology

Key Findings from APS Epidemiological Analysis and Forecast 

• According to DelveInsight’s estimates, the total prevalent cases of APS in the 7MM were approximately  310,800 in 2025.

• Among the EU4, Germany accounted for the highest number of prevalent cases of APS, followed by France, whereas Italy accounted for the lowest number of cases in 2025.

• The observed female predominance and earlier onset of APS highlight the importance of early screening, timely diagnosis, and tailored management strategies, particularly in women of reproductive age, to reduce thrombotic risk and improve pregnancy outcomes. 

• The prevalence of APS was 51.18% in the US population. Males had a lower prevalence of APS than females.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of APS, explaining its causes, signs and symptoms, and pathogenesis.

• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

Antiphospholipid Syndrome (APS) Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (epi‑based) Bottom‑up Forecasting

• 11-year Forecast 

• Patient Burden Trends (by geography)

Key Questions Answered

• What are the disease risks, burdens, and unmet needs of APS? What will be the growth opportunities across the 7MM concerning the patient population with APS?

• What is the historical and forecasted APSpatient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.

• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.